BioTech 365

MAY 11, 2021

Million Worldwide Recombinant DNA Technology Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com $609.8

Recombinant DNA Technology 40

Recombinant DNA Technology DNA Marketing 40

Pharmaceutical Technology

FEBRUARY 15, 2023

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

pharmaphorum

FEBRUARY 22, 2021

Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs. A single shot vaccine from Johnson & Johnson is also being reviewed by the FDA, which could also be approved in Europe in the coming weeks.

Vaccine 89

Vaccine Vaccination Recombinant DNA Technology Trials 89

Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Pharma Packaging Solutions

JUNE 30, 2023

Semi-Synthesized: Though the term “biologic” is accurate for the extracted materials listed above, it is more often used to describe therapeutics that are produced with recombinant DNA technology.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

Pharma Packaging Solutions

SEPTEMBER 22, 2023

There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Biologics are drug products that are manufactured using materials from living sources. What are Biosimilars?

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Pharma Packaging 52

Roots Analysis

JANUARY 21, 2024

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40